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Abstract 
Introduction and objectives. Congestive heart failure is associated with substantial morbidity and mortality and both 
its incidence and prevalence are high. Nevertheless, comprehensive data on this condition in Spain are lacking. The 
aim of this study was to determine the prevalence of congestive heart failure in Spain. 
Methods. A demographic study which involved the participation of 15 healthcare centers throughout Spain was 
carried out. In each health area, a random sample was taken of the population aged 45 years or more. These 
individuals were examined by their primary care physicians, who made their diagnoses using Framingham criteria. 
Individuals who satisfied criteria for congestive heart failure were referred to a cardiologist for confirmation of the 
diagnosis and for echocardiography. 
Results. Overall, 1776 individuals were evaluated. Their mean age was 64±12 years (range, 45-100 years) and 44% 
were male. Of these, 242 were referred to a cardiologist. The weighted prevalence of congestive heart failure was 
6.8% (95% confidence interval [CI] 4-8.7). The prevalence was similar in men (6.5%, 95% CI 4.7-8.4) and women 
(7%, 95% CI 4.4-9.6). When analyzed by age, the prevalence was 1.3% (0.4%-2.1%) in those aged 45-54 years, 5.5% 
(2.4%-8.5%) in those aged 55-64 years, 8% (4.2%-11.8%) in those aged 65-74 years, and16.1% (11%-21.1%) in 
those aged over 74 years. 
Conclusions. Prevalence of congestive heart failure in Spain is high, at about 7%-8%. The prevalence was similar in 
males and females, and appeared to increase with age. 
Resumen 
Introducción y objetivos. La insuficiencia cardiaca congestiva (ICC) tiene elevadas incidencia, morbilidad y 
mortalidad y una gran prevalencia. Sin embargo, no hay datos directos sobre este aspecto en nuestro país. El objetivo 
de nuestro estudio es evaluar la prevalencia de ICC en España. 
Métodos. Se diseñó un estudio poblacional en el que participaron 15 centros repartidos por toda España. Se 
seleccionó de forma aleatoria una muestra de la población de 45 o más años de edad atendida en cada área de salud, 
que fue estudiada por sus médicos de atención primaria. Se utilizaron los criterios de Framingham para el 
diagnóstico. Las personas con criterios de ICC fueron remitidas a una consulta de cardiología para confirmación 
diagnóstica y realización de ecocardiograma. 
Resultados. Se evaluó a 1.776 personas, con una media ± desviación estándar (intervalo) de edad de 64 ± 12 (45-100) 
años; eran varones el 44%. Se remitió a cardiología a 242 pacientes. La prevalencia ponderada de ICC fue del 6,8% 
(intervalo de confianza [IC] del 95%, 4%-8,7). La prevalencia fue similar en varones (6,5%; IC del 95%, 4,7-8,4) y 
en mujeres (7%; IC del 95%, 4,4-9,6). Por edades, la prevalencia fue del 1,3% (0,4%-2,1%) entre los 45 y 54 años; el 
5,5% (2,4%-8,5%) entre 55 y 64 años; el 8% (4,2%-11,8%) entre 65 y 74 años, y el 16,1% (11%-21,1%) en personas 
de 75 o más años. 
Conclusiones. La prevalencia de ICC en España es alta, en torno a un 7-8%. La prevalencia es similar en varones y 
mujeres, y parece aumentar con la edad. 
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Introduction  
Congestive heart failure (CHF) is becoming one of the main public health problems in developed 
countries. It is the cause of significant morbi-mortality in the general population and its incidence and 
prevalence are increasing due to the ageing of the population, improvements in health care, and improved 
survival in those with chronic diseases. The situation is exacerbated by the fact that CHF is the final stage 
of many heart diseases which have also seen significant improvements in survival.1,2 Although treatment 
and disease course for many heart conditions have improved, morbi-mortality in CHF has not decreased 
significantly. This is likely due to the fact that the CHF population are older and have higher rates of co- 
morbidity.3,4 The increase in morbidity is reflected in increased hospital admissions, with CHF being the 
main cause of medical hospital admissions in patients over 65 years of age.4,5 On the other hand, age-
adjusted mortality rates have decreased slightly in Spain.4,5  
Although in many developed countries CHF appears to have become more prevalent in recent years,5,6 
studies of prevalence are usually not carried out at the national level. In Spain, the only population-level 
study to date was performed in Asturias over 10 years ago (in 1996). The results indicated a prevalence of 
5% in the population aged 40 years or over.7 The prevalence of CHF in Spain is likely to have increased 
since then, due to the factors mentioned above. The present paper presents the results of the PRICE 
(Prevalencia de Insuficiencia Cardiaca en España, [Heart Failure Prevalence Study in Spain]) study. The 
study objective was to evaluate the prevalence of CHF in the general population aged 45 years or over in 
Spain.  
Methods   
The PRICE study was sponsored by the Heart Failure, Heart Transplant, and Alternative Treatment 
Section of the Spanish Society of Cardiology, and made use of the CHF units that participated in the 
BADAPIC (Base de Datos en Pacientes con Insuficiencia Cardíaca [Patients with Heart Failure 
Database]) registry.8 The 53 hospitals collaborating on the registry were initially sent an invitation to 
participate in the study.   
The invitation included a brief survey to determine whether centers met certain requirements for 
inclusion in the study. These included having access and fluid communications with the corresponding 
primary care network as well as having capacity for the extra consultations and echocardiograms required 
by the study. Furthermore, all primary care centers in the corresponding health care area were required to 
provide a list of the entire population covered by the area, stratified by age and sex. Of the 53 centers 
contacted, 22 confirmed they would be able to comply with requirements. A total of 15 hospitals and the 
55 health care centers corresponding to the same health care areas were included in the study (see 
Appendix): 3 in Asturias; 2 in Andalucía, Aragón, País Vasco, and Galicia; and 1 in Castilla-La Mancha, 
Murcia, Valencia, and Cantabria. Fieldwork was carried out in 2004 and 2005.  
Sampling Procedure   
Each hospital was required to include a given number of individuals aged ≥ 45. Individuals included 
were distributed between the participating centers in the health area and were selected by simple random 
sampling from the center’s population register of individuals aged ≥ 45 years. A total of 2703 individuals 
were invited to participate through a letter from their primary care physician which described the study 
objectives and procedures.  
Diagnostic Criteria and Clinical Examinations  
All participants were examined by their primary care physician to determine whether CHF was 
present. The modified Framingham criteria were used to decide on the presence of CHF (Table 1). A 
diagnosis of heart failure was assigned when there was a previous diagnosis of CHF confirmed after 
hospitalization or when 2 major criteria or 1 major and 2 minor criteria were present on examination. The 
clinician visit included assessment of the prior history of heart failure and cardiovascular risk factors in 
the medical record, a physical examination, an electrocardiogram, and a chest x-ray. Participants with a 
diagnosis of heart failure or with uncertain diagnosis were referred to the hospital for examination by a 
cardiologist. The cardiologist repeated the physical examination and evaluated the results of the ECG and 
chest x-ray. A Doppler echocardiogram was also performed. A final diagnosis of CHF was established 
when there were positive Framingham criteria and significant organic or functional anomalies on the 
Doppler echocardiogram (ejection fraction <45%; diastolic dysfunction with abnormal relaxation pattern, 
distensibility or pseudonormal pattern; a minimum of moderate mitral or aortic valve damage, or left 
ventricular hypertrophy). The cardiologist also established CHF etiology, functional capacity, and type of 
CHF (depressed systolic function was defined as left ventricular ejection fraction <45%, and preserved 
systolic function as ejection fraction ≥ 45%). In order to analyze the reliability of the primary care 
diagnosis and the agreement between specialists and primary care physicians, a random sub-sample of 5% 
of participants without clinical indications of CHF was included at the primary care visit and referred for 
assessment by a cardiologist. The hospital evaluation included a Doppler echocardiogram.                    
Table 1. Framingham Criteria (Modified) for the Diagnosis of Left Heart Failure 
  
Major criteria  Paroxysmal nocturnal dyspnea 
 Rales  
 S3 gallop 
 Radiographic cardiomegaly  
 Radiological signs of pulmonary edema 
Minor criteria Dyspnea on ordinary exertion 
 Nocturnal cough 
 Tachycardia >120 beats/min 
 Radiological pleural effusion 
 Weight loss >4.5 kg in 5 days in response to diuretic treatment 
  
 
Statistical Analysis   
To take into account limitations in sample selection, the sample was weighted to ensure that it was 
representative of the Spanish general population by age and sex. Weights were defined as the inverse of 
the probability of selection, assuming that the 15 hospitals selected were a random sample of all hospitals 
in Spain. It was also assumed that, while the prevalence of CHF may differ between different regions of 
Spain, these differences would not be related to the fact that a given hospital was part of the heart failure 
unit network. Likewise, we assumed that prevalence would be unrelated to the hospital’s degree of access 
to primary care in the area. Finally, the weights assigned were readjusted so that the weighted sample had 
the same distribution by age group and sex as the population of Spain according to the 2001 census data. 
The weight assigned to each patient reflects the number of individuals in the Spanish population 
represented by that patient, taking into account age group and sex.9 The sum of all the weights is therefore 
equal to the size of the Spanish population aged 45 or over. Weighted prevalences for CHF were 
calculated for the population as a whole as well as for specific age groups and by gender.   
Cohen’s kappa statistic10 was used to estimate agreement between the primary care physician’s and 
the cardiologist’s assessment. Results are presented as the percent agreement. The cardiologist’s 
diagnosis (which included the results of the Doppler echocardiogram) was considered the gold standard.11  
Point estimates and 95% confidence intervals (CI) are used to present the results. The stepwise 
sampling strategy was taken into account when calculating the degree of precision (the confidence 
intervals of the estimates).                              
Results  
A total of 1776 individuals participated in the study (66% of those invited to participate). Of these, 
242 were evaluated both at primary care level and by a cardiologist. The distribution of the final sample 
of participants evaluated only in primary care and at both primary care and hospital level is shown in 
Table 2. Table 3 shows the characteristics of the study sample. The mean (standard deviation [SD]) of the 
population evaluated was 64 (12) years; 44.1% were male. Table 2 also shows the sample distribution by 
10 year age splits and sex. Almost 64% of participants were living in towns or cities at the time of the 
study, compared to 36% who were living in rural locations. A total of 6.7% of the sample had a prior 
history of ischemic heart disease; 14.1% of diabetes; 29.5% of high blood pressure; 30.9% of 
hyperlipidemia; and 14.9% were current smokers. Of the overall sample, 4.1% had been diagnosed with 
heart failure during a previous hospital admission.   
  
Table 2. Distribution of Participants Attended in Primary Care and in Both Settings Means (Primary Care and Hospital) by Age 
Group and Sex 
 Setting for Evaluation Men, No. (%) Women, No. (%) Total, No. (%) 
     
Age, y     
45-54  Primary care 212 (27.1) 255 (25.7) 467 (26.3) 
 Both 14 (14.3) 31 (21.5) 45 (18.6) 
55-64  Primary care 217 (27.7) 268 (26.9) 485 (27.3) 
 Both 32 (32.7) 29 (20.1) 61 (25.2) 
65-74  Primary care 187 (23.9) 252 (25.4) 439 (24.7) 
 Both 25 (25.5) 45 (31.3) 70 (28.9) 
>75 Primary care 167 (21.3) 218 (22) 385 (21.7) 
 Both 27 (27.6) 39 (27.1) 66 (27.3) 
Total Primary care 783 (44.1) 993 (55.9) 1776 
 Both 98 (40.5) 144 (59.5) 242 
     
 
Table 3. Sample Characteristics (n=1776) 
 % 
  
Resident in urban area 63.9 




Personal antecedents  
Ischemic heart disease 6.7 
Diabetes 14.1 
Hyperlipidemia 33.8 
High blood pressure 30.9 
Obesity 29.5 
Cigarette consumption  
Active smoker 14.9 
Ex-smoker 19.6 
Previous diagnosis of heart failure 4.1 
  
 
The prevalence of CHF, by age group and sex, are shown in Table 4. In the overall sample, 6.8% 
(95% CI, 4.9-8.7) met the study definition for CHF. No difference in prevalence rates was observed by 
sex (6.5% in men compared to 7% in women), but there were differences by age group, with prevalence 
rising rapidly with age. In the 45 to 54 year-old age group, prevalence was 1.3%, compared to 5.5% in the 
55-64 year-old age group, 8% in the 65-74 year-old age group, and 16.1% in those aged 75 or over (Table 
4). The increase with age was similar in men and women (Table 4). Of those with CHF, 52% had 
depressed systolic function (left ventricular fraction <45%) and 48% had preserved systolic function 
(ejection fraction  ≥ 45%).   
  
Table 4. Weighted Prevalence by Age Group and Sex 
 Men Women Total 
    
Age, y    
45-54  1.3 (...-2.7) 1.2 (...-2.6) 1.3 (0.4-2.1) 
55-64  7.4 (1.3-13.5) 3.6 (1-6.2) 5.5 (2.4-8.5) 
65-74  7 (2.5-11.6) 8.8 (4.1-13.4) 8 (4.2-11.8) 
>75  15.6 (9.4-21.8) 16.4 (9.7-23) 16.1 (11-21.1) 
Overall  6.5 (4.7-8.4) 7 (4.4-9.6) 6.8 (4.9-8.7) 
    
 
Data are shown in percentages (95% confidence interval).  
There was 86% agreement between primary care physicians and cardiologists in terms of diagnosis. 
Agreement on specific criteria was  ≥ 90%, except for cardiomegaly (85.6%) and dyspnea on exertion 
(87.2%)                   
Discussion  
According to the results of our study, the prevalence of heart failure in Spain is high, at around 6.8% 
of the population aged 45 or over. The prevalence rate is similar in men and women and clearly increases 
with age, to 16% in men and women aged over 75 years. Prevalence is 8% in the 65-74 age group, 5.5% 
in the 55-64 age group, and 1.3% in the 45-54 age group. The overall prevalence found here (6.8%) is 
slightly higher than that found by Cortina et al7 in Asturias 8 years earlier (5%). In the earlier study, a 
total of 391 individuals were evaluated and the clinical examination was performed by cardiologists; in 
over 80% of cases, the examination included evaluation using Doppler echocardiogram. Our study, on the 
other hand, was based on assessment in primary care, which could lead to an underestimate of heart 
failure prevalence. Nevertheless, there was substantial agreement (86%) between assessments made in 
primary care and those made by the cardiologist.   
The prevalence rate for heart failure observed here represents a considerable increase from figures 
published over the last 10 years for western countries.5,6 Data from the Framingham study showed a 
prevalence for CHF of 1% in individuals over 40 years of age.12 Cleland et al13 also reported a prevalence 
of 1%, with an additional 2% of patients showing signs and symptoms of CHF after an exhaustive 
exploration (giving a total of 3%). In Minnesota, in the county of Olmsted, a prevalence of CHF of only 
2.2% was recorded between 1997 and 2000.14 The prevalence of CHF doubles with every decade of 
age,7,13 a finding which was confirmed in our study and which might, to a large extent, explain the 
increase in prevalence in CHF over the last 10-20 years. Another contributing and related factor, is the 
improvement in treatments for CHF and the associated decrease in mortality, as indicated in recent 
studies from Europe3  and the United States.15 In Spain, mortality from CHF has also decreased recently,
4,5 
although it remains the third most important cardiovascular cause of death after ischemic heart disease 
and stroke, in men and women. It has been shown to be responsible for 15% of total cardiovascular 
mortality (11% in men and 19% in women).16  
Data from some studies have confirmed the increase in the prevalence of CHF in recent years16,17 and 
suggest that prevalence will rise even more over the next 10-15 years. Stewart et al17 calculated that the 
prevalence of CHF in Scotland will increase by 31% in men and 17% in women between the year 2000 
and 2020. Our results are in line with those forecasts, as well as with previous observations of a high 
prevalence of heart failure in women16 and in older age groups.17 As the average age of the population will 
almost certainly continue to rise and as life expectancy in women continues to exceed that of men, a heart 
failure “epidemic” appears increasingly likely, with the consequent need for greater treatment resources. 
Another interesting aspect of our data is that, of the total of heart failure cases found, ejection fraction 
was preserved in approximately half. This supports the results of recent studies in the United States.14  
Limitations   
Our study has some limitations which stem largely from the methodology used. The logistic 
complexity of a study of this type, which was performed throughout Spain, largely in primary care 
centers, and without financial remuneration for participating investigators, meant that the initial selection 
of centers was not randomized as it was considered essential to include investigators who would be 
committed to the study. This meant that large urban areas are under-represented and could, in addition, 
theoretically lead to a bias towards a higher number of CHF diagnoses. Nevertheless, confirmation of the 
diagnosis by cardiologists reduces that possibility. Agreement between primary care physicians and 
specialists, both in terms of the overall diagnosis of CHF as well as on specific clinical criteria, was very 
high (86% for the overall diagnosis). Another important source of bias could have been in the final 
selection of patients, though this was reduced by using random selection, and an acceptable degree of 
participation was also achieved. Finally, we have no information regarding prevalence in institutionalized 
patients and, in spite of the precautions taken and the high level of agreement between primary and 
specialist care, the possibility of under-diagnosis in primary care remains. Both aspects might lead to an 
underestimation of true prevalence rates.  
Conclusions   
Taking into account the limitations mentioned above, the results of our study indicate that the 
prevalence of CHF in Spain in the population aged 45 years or over is high, at almost 7%. The prevalence 
rates are similar in men and women, and increase with age. These data, which are the first to be obtained 
in a nationwide study, can be used for future estimates of the magnitude of CHF in Spain and, with the 
aid of real local data, can be used to guide resource allocation for the management of the disease.  
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